CureLab Veterinary Appoints Seasoned Industry Leader Alexis Nahama, DVM, as Executive Vice-President
In his most recent roles as SVP of corporate development at Sorrento Therapeutics and president of ARK Animal Health (a division of Sorrento Therapeutics), Dr. Nahama spearheaded high-priority drug development programs and established global strategies for commercial operations and strategic licensing. His leadership extended to overseeing R&D, business development, and licensing pipelines, ensuring the timely delivery of innovative health solutions for both animals and humans.
“Dr. Nahama’s proven track record in advancing high-need drug development programs, setting global strategies for commercial operations, and securing strategic licensing agreements makes him an invaluable addition to our leadership team,” said Alexander Shneider, Ph.D., founder and chairman of the board of CureLab Veterinary. “His deep understanding of the complex landscape of oncology drug development will be crucial as we navigate the path to commercialization for our groundbreaking cancer therapies.”
In this new role at CureLab Veterinary, Dr. Nahama will support comprehensive company development efforts, including business development, investor relations, cross-team communications, and external licensing. He will focus on establishing strategic partnerships, securing investment, and building a robust infrastructure to support the successful launch and commercialization of the company’s innovative cancer therapies.
“I am eager to leverage my experience in drug development, commercialization and professional network to help CureLab Veterinary realize its full potential,” said Dr. Alexis Nahama. “The company's innovative approach to cancer treatment represents a significant and much needed advancement applicable to veterinary medicine, and I am confident that we can make a meaningful impact on the lives of pets and their families.”
Dr Nahama currently supports other companies and is committed to non-competitive strategic projects for animal health companies, as an active investor and senior consultant. Curelab expects to expand his role further as the company secures additional funding and prepares for pivotal clinical trials.
ElenaVet™, a p-62 DNA plasmid that has been tested on a variety of animals and has demonstrated efficacy in reducing and attenuating pro-inflammatory mediators by changing the tumor microenvironment and by decreasing the tumor microenvironment. The process of chronic inflammation leads to cells becoming metaplastic and then cancerous. Many cancers can be treated with ElenaVet, as well as chronic inflammatory conditions in dogs and cats.
CureLab Veterinary is a biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company’s mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners. To learn more, visit curelabveterinary.com.
